Emerging drugs to treat squamous cell carcinomas of the head and neck.
about
Emerging role of sphingosine-1-phosphate signaling in head and neck squamous cell carcinomaIdentification of epidermal growth factor receptor (EGFR) genetic variants that modify risk for head and neck squamous cell carcinomaOptical metabolic imaging of treatment response in human head and neck squamous cell carcinomaNovel Pactamycin Analogs Induce p53 Dependent Cell-Cycle Arrest at S-Phase in Human Head and Neck Squamous Cell Carcinoma (HNSCC) CellsClinical update on cancer: molecular oncology of head and neck cancerImmunological treatment options for locoregionally advanced head and neck squamous cell carcinomaCaspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth.Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring response.Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers.Heparanase induces signal transducer and activator of transcription (STAT) protein phosphorylation: preclinical and clinical significance in head and neck cancerMetabolic Imaging of Head and Neck Cancer OrganoidsNew approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).Beyond tobacco in head and neck squamous cell cancers… Emerging era of molecular targeted therapy and virtual biopsyThe cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell carcinomaEGFR tyrosine kinase inhibition induces autophagy in cancer cells.Targeting proliferation and survival pathways in head and neck cancer for therapeutic benefitMolecular characterization of head and neck cancer: how close to personalized targeted therapy?Impact of human papillomavirus on oropharyngeal cancer biology and response to therapy: implications for treatment.Expression of EGFR, VEGF, and NOTCH1 suggest differences in tumor angiogenesis in HPV-positive and HPV-negative head and neck squamous cell carcinoma.Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop.Co-expression of perforin and granzyme B genes induces apoptosis and inhibits the tumorigenicity of laryngeal cancer cell line Hep-2.Attenuation of cancer-initiating cells stemness properties by abrogating S100A4 calcium binding ability in head and neck cancers.Targeting RSK2 in human malignancies.Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer.Translational genomics and head and neck cancer: toward precision medicine.Drug Loaded Gingival Mesenchymal Stromal Cells (GinPa-MSCs) Inhibit In Vitro Proliferation of Oral Squamous Cell Carcinoma.In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas.Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer.Integrative genomic analysis identifies ancestry-related expression quantitative trait loci on DNA polymerase β and supports the association of genetic ancestry with survival disparities in head and neck squamous cell carcinoma.Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin.FRA1 promotes squamous cell carcinoma growth and metastasis through distinct AKT and c-Jun dependent mechanisms.Regulation of cell migration via the EGFR signaling pathway in oral squamous cell carcinoma cells.Emerging drugs for head and neck cancer.Anti-oncostatin M antibody inhibits the pro-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma.Overexpression of CXCR4 promotes invasion and migration of non-small cell lung cancer via EGFR and MMP-9.Upregulation of cell cycle genes in head and neck cancer patients may be antagonized by erufosine's down regulation of cell cycle processes in OSCC cells.Preclinical evaluation of near-infrared (NIR) fluorescently labeled cetuximab as a potential tool for fluorescence-guided surgery.
P2860
Q26744051-A6D2BEEA-8BD7-4BBA-A5A5-413F9143204AQ28385950-B1729C6A-25EE-4317-8ADB-944C02823224Q28540413-25C88F04-53C4-4CFF-9ADA-84766B2BC1C2Q28546975-C30161DE-93E2-4223-8EF5-911B91CC532BQ33695197-77D76CCF-7B0D-4EBE-B44D-C36B86B20295Q34181954-5E0E20E3-9FF8-47BE-AC58-F514EFB4F5B3Q34345398-F68D5B6A-BCCB-49ED-A76C-C79F2053352BQ35102025-0BDB556D-8568-4047-91FF-36E18EAA2FB7Q35223807-6DE860E1-2E53-451F-ADBE-45D3A5038DDBQ35741628-06B8CA2D-1E82-4B6F-9B9E-9C11F8BA8EA4Q35838889-807D35BA-A9C1-4569-94F7-018FA128DE2BQ36252747-79A1EADC-4F64-4BAD-BF7A-DB60EDC4D08FQ36303845-3B1835A1-C653-4BE1-A029-87A354651D7AQ36344288-111F81D0-52D7-4771-898A-B2ECD6EB29D4Q36458158-7638BC35-DEE2-4E92-B9B1-C74E2E7F5A7DQ36524211-CD022144-A11C-479A-86DE-2D8C68313434Q36713669-B5B5C13C-DD29-420E-B691-DD8E4F5E7573Q37000422-2BFF8576-65DD-4F3B-8E91-8EF0CF37C6E4Q37087450-C0315B4D-6547-4297-B6B5-6E0AD17535CFQ37299934-217AC678-17BA-4300-A702-ED1D8281E3C0Q37494943-3F3C632C-DF88-4649-8F1E-1FD81F24879EQ37676738-939D6D9F-2F04-4B9D-9B6F-2523C19BB20AQ37694734-DCAD2402-50AA-4984-8D62-87EB3A0D4299Q37802388-4D30AA2E-94AF-4066-97D0-B43EFE83B695Q38240998-5E3CB5BF-F27B-4748-BFA9-7F8D005B0ECAQ38241804-AA29A695-A19A-4AEB-9763-3A92BDE6D9E6Q38637527-7EF91C5F-1244-42CC-B6A3-2F386DC0E07CQ38859126-C67D7F93-3169-42CA-8090-53398EACEE0EQ39015086-ADD54794-3D86-479D-9EC9-6F3FB54E5FAFQ39139789-E923B039-4FD0-4F2F-BD13-1519D8624171Q39191981-94775A1B-F71F-4DCD-A6C6-36285861F36DQ39289240-C9ADC083-849E-40AA-8B67-3714331CB759Q39545323-C0BF4C66-3DEC-4C54-BA0D-15E6C54642D6Q39796050-3D2AF89A-4C42-4404-9902-3083261E3B07Q41814094-7DE39F71-220D-4391-AA59-79FCE6ED472CQ45874449-F928593B-1B82-45FF-937A-CDED2244979DQ47368243-B5954125-0669-484A-A40F-F32001CD6CEFQ47654279-F178B74F-0308-4C97-BBF2-23676B2E5501Q49787815-FE608C12-61B0-4710-997F-14A5224BAB72Q51634494-A2F58E74-9001-4FC9-A3DE-72EB984646FA
P2860
Emerging drugs to treat squamous cell carcinomas of the head and neck.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Emerging drugs to treat squamous cell carcinomas of the head and neck.
@ast
Emerging drugs to treat squamous cell carcinomas of the head and neck.
@en
type
label
Emerging drugs to treat squamous cell carcinomas of the head and neck.
@ast
Emerging drugs to treat squamous cell carcinomas of the head and neck.
@en
prefLabel
Emerging drugs to treat squamous cell carcinomas of the head and neck.
@ast
Emerging drugs to treat squamous cell carcinomas of the head and neck.
@en
P2860
P1476
Emerging drugs to treat squamous cell carcinomas of the head and neck.
@en
P2093
Christopher Fung
P2860
P304
P356
10.1517/14728214.2010.497754
P407
P577
2010-09-01T00:00:00Z